AVEO Oncology has published the long-term follow-up results from Study 902, where patients were treated with tivozanib (Fotvda) as second-line treatment in advanced renal cell carcinoma, in the European Journal of Cancer. The publication, titled “Efficacy of Tivozanib Treatment after Sorafenib in Patients with Advanced Renal Cell Carcinoma: Crossover of a Phase 3 Study”, was published online first and is available here.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
